StemCell Therapy

A few months ago, I attended a forum on the politics and economics of disability. My impression was that the audience consisted mainly of people with disabilities -- an impression that has changed with time. Whatever the proportions may actually have been, my judgment was probably skewed by self-consciousness, and not just the usual awkwardness of finding a seat after the presentation was well underway. It had taken root long before I got to the room.

"Able-bodied" and "disabled" are categories that function in society at large as necessary and common-sensical, and they are weighted such that the first is posited as normal and predominant, and as such effectively invisible, while the other is an exceptional condition, making it, oddly, both conspicuous and ignorable as circumstances may dictate. With hindsight I am not at all sure more people at the talk had wheelchairs or canes than were present at other talks I attended at the conference. Besides, not every disability involves such a clear marker.

But since disability itself was the topic of the hour, the fact that I did not need any such assistance registered much more sharply than it ordinarily would. Eyeglasses didn't count. Experiential norms prevailing outside the room were not taken for granted, as became even more clear following the speaker's presentation. A number of people pointed out that no American Sign Language interpreter was present. Somehow I had not noticed. Not noticing certain things is a luxury you generally aren't even aware of enjoying.

As binary oppositions go, "able-bodied/disabled" proves much less stable than it appears. It's not just that the most gifted athlete or graceful dancer may be one bullet or automobile accident away from an irrevocable change in status. As mentioned, wearing glasses allows me to function as fully able, but they are a prosthesis for the lenses in my eyes, quite as much a wheelchair is for a paraplegic's legs. And the process of aging has a way of erasing the bright line between ability and its malfunctions. Time is not on the side of the able-bodied. With aging, the binary opposition runs right through the brain, so to speak. Jokes about "having a senior moment" acknowledge (and deflect) this reality. Our long-term command of the powers of attention and memory is contingent at best.

One of the things the reader can take away from George Estreich's Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves (MIT Press) is a heightened sense of how damaging it can be to think of "the disabled" in terms of a distinction between "us" and "them." An instructor in writing at Oregon State University, Estreich is also the author of The Shape of an Eye: A Memoir, about raising his daughter Laura, who has Down syndrome. I haven't read it, but she reappears throughout Fables and Futures without that making the book a memoir, exactly.

"Writing about Laura has its complications," Estreich notes. "For each sentence, I could add a page of narrative caveats, a fine print to govern the legal interpretation of anecdote: 'This positive description is not meant to inspire Though the author has strong opinions on a range of social issues, he declines to weaponize his daughter in their service. Laura is not an example in an argument She is a person, and by describing her the author intends to suggest what she is like and raise questions about the world she enters. This work is related to, yet different from, his work as a parent, which is to help her find, in every sense, her place.' Behind these caveats is the wish to control interpretation, and behind that vain hope is, in no particular order, a writer's ego, a father's protectiveness, and a deep familiarity with the average Internet comment section."

That is quite a few knives to juggle at the same time. And the list does not even include the issue on which Estreich concentrates here: the advancing biotechnology of prenatal testing and genetic editing. The book is a sort of intellectual travelogue, the author thinking his way across a landscape that is changing faster than it can be captured in concepts. When he attends an event in New Orleans that doubles as a professional conference for genetic counselors and a trade show for biotech companies, he notes, "The uneasy tension between old and new brought on by biotech: the more artifice the project requires, the more its advocates retail images of naturalness and purity." The quest to render the woolly mammoth "de-extinct" coexists with strong an implicit and largely unacknowledged strain of 21st-century eugenics.

Given the murderous consequences of one especially vehement form, we tend to think of eugenics as prone to goose-stepping. But a tangent from the memory of his daughter's participation in a county fair leads Estreich back to the era of Better Babies and Fitter Families contests at Midwestern state fairs, in which whole families underwent exams and answered questionnaires to determine which was freest from inherited defects. "If human improvement is on stage," he writes, "disability-based metaphors are usually skulking in the wings."

The author's worry -- which is also a father's worry -- concerns the possible cascade of effects of "our rapidly increasing, fine-grained knowledge of genetic variation." A culture that takes technological development as inevitable is dangerous enough, to itself and others, without having the option of decision making that "invoke[s] abnormality, a word capacious enough to hold everything and everyone considered different and undesirable." Estreich is uncommonly adept at presenting both experiences and ideas in layers, without the structure itself becoming either unmanageable or distracting. Anyone who reads it should expect the wheels in their head to keep spinning for a while afterward.

Read the original post:
Review of George Estreich, 'Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves' (opinion) - Inside Higher Ed

Biotechnology-Based Chemical Market are items gotten from natural roots, for example, feedstock, plants, harvests, trees, and organic waste. This will benefit the reports users, that evaluates their position in the market as well as create effective strategies in the near future. They are a reasonable option in contrast to traditional synthetic concoctions and will assume a noteworthy job in decreasing the dependence on non-renewable energy sources. This can prompt diminished carbon discharge levels and keep up the biological parity. Lignocellulose is the most generally accessible crude material utilized for the creation of biofuels.

The report of CMFE Insights the Industrial substance application is foreseen to command the worldwide Biotechnology-Based Chemical Market growing CAGR of +16% during forecast period.

The report shields the development activities in the Biotechnology-Based Chemical which includes the status of marketing channels available, and an analysis of the regional export and import. The report ends with an inference for the global market as it was in industry. Researchers of this research report throw light on demand-supply chaining in the market. The forward-disapproved of people supporting the improvement of bio-based synthetic substances, specialists have been growing new sources and applications for Biotechnology-Based Chemical Market around the globe, delivering promising outcomes.

Request A sample copy of this report at https://www.cmfeinsights.com/request-sample.php?id=46666

The Report includes Several Company Profiles of who are market key players:

Biotechnology-Based Chemical Market by region:

The significant sorts of biotechnology are red, green, white, and blue biotechnology. Red biotechnology includes medicinal procedures, white biotechnology which is otherwise called dark biotechnology is primarily utilized in mechanical procedures, green biotechnology includes agrarian biotech procedures and blue biotechnology involves marine and amphibian procedures. Biotechnology-Based Chemical Market has wide applications crosswise over modern territories, for example, horticulture, prescription, sustenance generation, human services, and yield creation.

Get up to 40% Discount on this report at https://www.cmfeinsights.com/ask-for-discount.php?id=46666

Market by Type

Market by Application

The application, of worldwide Biotechnology-Based Chemical Market compounds is isolated into mechanical synthetic compounds, agribusiness, pharmaceuticals, and others. Leading key players have been profiled to get a clear insight into the businesses on the basis of successful strategies of the top level companies. Along with this, it also offers competitive significance among the several traders by presenting the facts and figures of market shares.

In this study, the years considered to estimate the market size of Biotechnology-Based Chemical Market are as follows:

About Us : CMFE Insights caters to clients needs by elucidating the power of innovation, thus thriving on business innovations. Our mission is to guide global businesses through our comprehensive market research reports. Through our infrastructural competence of digital transformations, we orchestrate escalated market efficiency for our clients by presenting them with capable growth opportunities in the global market scenario. Through the experienced eye of our research associates we help our clients to envision a flourishing future. CMFE Insights techniques is a perfect blend of both qualitative and quantitative modes, on basis of which we provide our clients with syndicated research reports to further enhance their strategic organizational decisions. CMFE Insights helps clients to build a pragmatic future in the innovative market industry.

Contact :

CMFE Insights

Jay S

+44 7537 121342

Office 271

321 323 High Rd

Chadwell Heath

RM6 6AX UK

sales@cmfeinsights.com

http://www.cmfeinsights.com

Read more:
Exclusive Research on Biotechnology-Based Chemical Market by CMFE Insights with Leading Players Sarnia-Lambton Research, UK and Norway business...

From the gene-editing powers of CRISPR-Cas9 to the creation of clean meat technologies, the biotechnology field continues to top one new development with another in rapid succession, and because of this innovative velocity, there is an increasing need for biotech leaders who understand both the science and the business of this ever-expanding field.

Where do women fit into this process? Do they face the same gender parity issues that they confront in other areas of science, technology, engineering and math, or STEM? What challenges should they prepare for as they launch a career in biotech?

A top-notch panel of scientists and entrepreneurs came together on Sept. 26, 2019, to answer these questions at the Katz School of Science and Healths first fall event for Women in Bio. Leading Biotech and Healthcare Organizations from Early to Late Stage, was co-organized by Dr. Rana Khan, director of the MS in Biotechnology Management and Entrepreneurship Program at the Katz School, and the New York Chapter of Women in Bio, the national organization for women in life sciences.

Panelists included Dr. Christina Brennan, vice president of clinical research, Northwell Health; Dr. Jeanne Magram, chief scientific officer, Quentis Therapeutics; Dr. Sandra Saldana, CEO and co-founder of Alva Health and adjunct professor at Yeshiva University; and Dr. Mani Mohindru, CFO and chief strategy officer at Cara Therapeutics.

The event was a resounding success with great speakers and engaged attendees, one of whom described it as a difference-making experience. It was empowering to sit in a roomful of professional women, in top roles, opening their hearts about the challenges they are going through. I came away with two new connections that are meaningful to my career. Thank you, YU, for hosting such a memorable event.

Original post:
Women in Biotech: Katz Event Explores the Rewards and Challenges of a Career in Biotechnology - Yu News

TEL AVIV, Israel, Nov. 19, 2019 /PRNewswire/ --Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

Recent Highlights

"Our clinical and regulatory teams remained focused during the third quarter and the more recent positive developments position us to achieve our goals, both in the U.S. and Israel," commented Dr. Shai Yarkoni, Chief Executive Officer. "In the U.S., the IND approval is a significant achievement and represents our first-ever FDA IND in the U.S., with Washington University School of Medicine. In Israel, our Phase 1/2 clinical study of ApoGraft is progressing slowly and we expect to complete the recruitment around the end of the year."

"With our prudent use of cash during the third quarter and the anticipated cash usage needs over the coming quarters, we continue to believe we have the resources to execute our clinical and regulatory plans for the foreseeable future," said Eyal Leibovitz, Chief Financial Officer.

ThirdQuarter 2019 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2019 (U.S. $1 = NIS 3.482).

Strategic Review Progress Update

On May 16, 2019, the Company disclosed that it commenced plans to explore strategic alternatives to maximize shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, including in other business fields than the Company's in-licensing, or other strategic transaction involving the Company or its assets. The Company continues to evaluate business development opportunities and will keep investors informed as they mature or warrant investor disclosure.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Nine months

ended

Nine months ended

Three months ended

September 30,

September 30,

September 30,

2019

2019

2018

2019

2018

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

2,743

9,551

9,473

2,465

4,125

General and administrative expenses

2,249

7,832

11,001

2,768

3,929

Operating loss

4,992

17,383

20,474

5,233

8,054

Financial expenses (income) due to warrants exercisable into shares

(2,303)

(8,020)

(2,935)

(910)

(1,320)

Other financial expenses (income), net

393

1,369

(1,177)

489

64

Total comprehensive loss

3,082

10,732

16,362

4,812

6,798

Loss per share:

Basic and diluted loss per share

0.015

0.051

0.127

0.021

0.052

Basic and diluted loss per ADS

0.30

1.02

2.54

0.42

1.04

Weighted average number of shares outstanding used to compute basic and diluted loss per share

208,771,303

208,771,303

129,139,278

224,087,799

130,192,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

ASSETS

Convenience

translation

September 30,

September 30,

December 31,

2019

2019

Here is the original post:
Cellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results - PRNewswire

The global Food Biotechnology industry research report offers a detailed analysis of the current status of the market 2019. This extensive Global Food Biotechnology Market research report contains a brief on industry trends that can guide the business operators in the industry to get an idea of the market and strategize for their business development accordingly. The research report studies the market size, Food Biotechnology industry share, growth rate, key segments, CAGR (%) and key drivers. At the start, the report offers a basic introduction to the Food Biotechnology market including definitions, applications, classifications and industry chain analysis. The study serves as the international Food Biotechnology market consist of development past, competitive landscape study, and advancement states of Food Biotechnology in major geographical regions.

Get a sample of the report from https://www.orbisreports.com/global-food-biotechnology-market/?tab=reqform

Secondly, Food Biotechnology manufacturing processes and cost study are discussed as well as development policies and plans are also included. This Food Biotechnology market research report also gives the data on import/send out, supply-demand, and Food Biotechnology consumption values along with cost, revenue and gross margin by worldwide regions. This Food Biotechnology report will surely help you to understand and apply the ideas and guide you in making strong decisions. The world Food Biotechnology industry was valued in 2019 is XX Mn US$ and is evaluates to be XX Mn US$ forecasting to 2024, with a perspective CAGR of X.X %.

Food Biotechnology Market Major Manufacturers:

ABS GlobalArcadia BiosciencesAquaBounty TechnologiesBASF Plant ScienceBayer CropScience AGCamson Bio Technologies LtdDow AgroSciences LLCDuPont PioneerEvogene LtdHy-Line InternationalKWS GroupMonsantoOrigin Agritech LimitedSyngenta AG

The aim of Food Biotechnology report is to give an idea to the readers in making firm business decisions based on market latest trends and upcoming market improvement estimates in forecast years. The study contains Food Biotechnology market contributors including vendors/traders, buyers/distributors/, suppliers/sellers. Their Food Biotechnology marketing strategies are also provided. Global Food Biotechnology report analyses the historical data regarding the market growth, Food Biotechnology market scope and also offers the current and Food Biotechnology market upcoming information. The study of major growth opportunities and challenges to the Food Biotechnology market is included.

Food Biotechnology Market Types Are:

Transgenic CropsSynthetic Biology Derived Products

Food Biotechnology Market Applications Are:

AnimalsPlantsOther

For more Information or Any Query Visit: https://www.orbisreports.com/global-food-biotechnology-market/?tab=discount

The worldwide Food Biotechnology industry report offers a thorough study of the Food Biotechnology market. The report Food Biotechnology focuses industry vision from experts. An in-depth segmentation of the Food Biotechnology industry has been provided in the report. Moreover, the world Food Biotechnology industry report also includes the sub-segments. The key sector, the emerging and leading sectors, together with their growth stats have been cited in the Food Biotechnology market report.

After a brief outlook of the global Food Biotechnology market, the report studies the market dynamics. The major drivers helping Food Biotechnology market growth and the major constraints inhibiting Food Biotechnology market growth are provided in this report. In addition, the Food Biotechnology industry report also gives the threats and challenges that companies in the Food Biotechnology market need to focus on. The most influencing trends that will give the structure the Food Biotechnology market during the forecasting prospect are also provided in this report. Furthermore, the report expands on the regulatory scheme governing the Food Biotechnology market and its possible effects on the market in the foreseeable horizon.

The insight analysis on Food Biotechnology research report provides:

The evaluated Food Biotechnology growth rate together with size and market share over the forecast period 2019-2024. The primary factors estimated to drive the Food Biotechnology Market for the forecasting period 2019-2024. The major Global Food Biotechnology market regulatory bodies and what has been their business expanding strategy for leading so far. Influential trends shaping the growth probabilities of the Food Biotechnology Market.

In-depth and complete business outlook, Food Biotechnology market revenue study, business expansion strategies, and SWOT analysis of the major leading players have been served in the report. Vendors in the Worldwide Food Biotechnology market are focusing to explore their operations to developing regions. More, companies in the Food Biotechnology market are concentrating on innovation and standing their Food Biotechnology products at competitive prices. A detailed analysis of Food Biotechnology supply chain in the report will help readers to understand Food Biotechnology market clearly.

Click here to see full TOC https://www.orbisreports.com/global-food-biotechnology-market/?tab=toc

Read the original here:
Food Biotechnology Market 2019| 2019 Applications, Types and Growing Trends, Share 2024 - Eastlake Times

The 74 rating InvestorsObserver gives to Jounce Therapeutics Inc (JNCE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, JNCEs 74 overall rating means the stock scores better than 74 percent of all stocks.

Click Here to get the full Stock Score Report on Jounce Therapeutics Inc (JNCE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Jounce Therapeutics Inc (JNCE) stock is trading at $5.81 as of 10:05 AM on Thursday, Nov 14, a rise of $0.22, or 3.86% from the previous closing price of $5.59. The stock has traded between $5.62 and $6.19 so far today. Volume today is 195,167 compared to average volume of 163,071.

To see InvestorsObservers Sentiment Score for Jounce Therapeutics Inc click here.

Read the original post:
Where Does JNCE Stock Rank in the Biotechnology Industry? - InvestorsObserver

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should PDS Biotechnology (NASDAQ:PDSB) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for PDS Biotechnology

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, PDS Biotechnology had cash of US$17m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through US$12m. So it had a cash runway of approximately 17 months from September 2019. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

NasdaqCM:PDSB Historical Debt, November 12th 2019

Because PDS Biotechnology isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Remarkably, it actually increased its cash burn by 673% in the last year. With that kind of spending growth its cash runway will shorten quickly, as it simultaneously uses its cash while increasing the burn rate. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

While PDS Biotechnology does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash to drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

PDS Biotechnology has a market capitalisation of US$15m and burnt through US$12m last year, which is 85% of the company's market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock.

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought PDS Biotechnology's cash runway was relatively promising. Considering all the measures mentioned in this report, we reckon that its cash burn is fairly risky, and if we held shares we'd be watching like a hawk for any deterioration. For us, it's always important to consider risks around cash burn rates. But investors should look at a whole range of factors when researching a new stock. For example, it could be interesting to see how much the PDS Biotechnology CEO receives in total remuneration.

Story continues

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Read the original:
PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely - Yahoo Finance

The 59 rating InvestorsObserver gives to Forty Seven Inc (FTSV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, FTSVs 59 overall rating means the stock scores better than 59 percent of all stocks.

Click Here to get the full Stock Score Report on Forty Seven Inc (FTSV) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Forty Seven Inc (FTSV) stock is trading at $10.31 as of 10:05 AM on Thursday, Nov 14, a rise of $0.12, or 1.18% from the previous closing price of $10.19. The stock has traded between $10.28 and $10.57 so far today. Volume today is below average. So far 51,681 shares have traded compared to average volume of 211,996 shares.

To see InvestorsObservers Sentiment Score for Forty Seven Inc click here.

Visit link:
Where Does FTSV Stock Rank in the Biotechnology Industry? - InvestorsObserver

Total Health Institute Reviews

Chicago, IL, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Dr. Keith Nemec the clinic director ofTotal Health Institute in Chicago has received yet another fellowship in his advanced research. Most recently Dr. Nemec received his fellowship in Stem Cell Therapy to add to his other fellowships in Regenerative Medicine and Integrative Cancer Therapies.

Dr. Nemec has overseen patient care for the last thirty-five years at Total Health Institute which is an alternative and integrative medical facility. Total Health Institute has seen over 10,000 patients who have traveled from around the world to seek Dr. Nemecs guidance in their healing journey.

Total Health Institute uses unique approach developed by Dr. Nemec called theSystems Sequence Approach to balance cellular communication between the cells, tissues, organs, glands and systems of the body. Dr. Nemec explains It is like knowing the combination to open the lock to complete healing. To open this lock, you must not only know the right systems to balance but also in the right sequence.

Dr. Keith Nemec is very excited about the research in stem cells and stem cell therapy that is why he focused his concentration in this area. According to Dr. Nemec All health and healing starts at the stem cell level. Whether a person has cancer, autoimmune disease or chronic diseases of aging they are all involving stem cells. In cancer, an inflammatory environment has mutated a normal stem cell into a cancer stem cell which is not killed with either chemotherapy nor radiation. This is why many times with conventional cancer treatment alone one tends to see improvements for a season but then return the cancer stem cell retaliates with a vengeance. Dr. Nemec also states Since all cells come from a base stem cell then the answer to all chronic disease can be found in activating the stem cells to produce an anti-inflammatory niche and continual healthy cell renewal.

Dr. Nemec is a member of the American Academy of Anti-Aging Medicine which is the largest and most prestigious group of Regenerative and Anti-Aging Medicine doctors in the world. He received his masters degree in Nutritional Medicine from Morsani College of Medicine. He has also published 5 books including: The Perfect Diet, The Environment of Health and Disease, Seven Basic Steps to Total Health and Total Health = Wholeness. Dr. Nemec has also published numerous health articles including: The Single Unifying Cause of All Disease and The answer to cancer is found in the stem cell and for 18 years he hosted the radio show Your Total Health in Chicago AM1160.

Total Health Institute boasts all 5 starreviews on RateMDs, an A+ rating onBBBand is top rated on Manta.

(630) 871-0000Keith@thi.co

Go here to read the rest:
Leading Alternative Healing Director of Total Health Institute Reviews and Receives 3rd Fellowship in Stem Cell Therapy - Yahoo Finance

MEDIA CONTACT

Available for logged-in reporters only

Newswise Irvine, Calif. November 15, 2019 Researchers from the University of California, Irvine developed a breakthrough cell therapy to improve memory and prevent seizures in mice following traumatic brain injury. The study, titled Transplanted interneurons improve memory precision after traumatic brain injury, was published today in Nature Communications.

Traumatic brain injuries affect 2 million Americans each year and cause cell death and inflammation in the brain. People who experience a head injury often suffer from lifelong memory loss and can develop epilepsy.

In the study, the UCI team transplanted embryonic progenitor cells capable of generating inhibitory interneurons, a specific type of nerve cell that controls the activity of brain circuits, into the brains of mice with traumatic brain injury. They targeted the hippocampus, a brain region responsible for learning and memory.

The researchers discovered that the transplanted neurons migrated into the injury where they formed new connections with the injured brain cells and thrived long term. Within a month after treatment, the mice showed signs of memory improvement, such as being able to tell the difference between a box where they had an unpleasant experience from one where they did not. They were able to do this just as well as mice that never had a brain injury. The cell transplants also prevented the mice from developing epilepsy, which affected more than half of the mice who were not treated with new interneurons.

Inhibitory neurons are critically involved in many aspects of memory, and they are extremely vulnerable to dying after a brain injury, said Robert Hunt, PhD, assistant professor of anatomy and neurobiology at UCI School of Medicine who led the study. While we cannot stop interneurons from dying, it was exciting to find that we can replace them and rebuild their circuits.

This is not the first time Hunt and his team has used interneuron transplantation therapy to restore memory in mice. In 2018, the UCI team used a similar approach, delivered the same way but to newborn mice, to improve memory of mice with a genetic disorder.

Still, this was an exciting advance for the researchers. The idea to regrow neurons that die off after a brain injury is something that neuroscientists have been trying to do for a long time, Hunt said. But often, the transplanted cells dont survive, or they arent able to migrate or develop into functional neurons.

To further test their observations, Hunt and his team silenced the transplanted neurons with a drug, which caused the memory problems to return.

"It was exciting to see the animals memory problems come back after we silenced the transplanted cells, because it showed that the new neurons really were the reason for the memory improvement, said Bingyao Zhu, a junior specialist and first author of the study.

Currently, there are no treatments for people who experience a head injury. If the results in mice can be replicated in humans, it could have a tremendous impact for patients. The next step is to create interneurons from human stem cells.

So far, nobody has been able to convincingly create the same types of interneurons from human pluripotent stem cells, Hunt said. But I think were close to being able to do this.

Jisu Eom, an undergraduate researcher, also contributed to this study. Funding was provided by the National Institutes of Health.

About the UCI School of Medicine: Each year, the UCI School of Medicine educates more than 400 medical students, as well as 200 doctoral and masters students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

The rest is here:
Researchers develop cell therapy to improve memory and stop seizures in mice following traumatic brain injury - Newswise

How can we confront the faith-health care gap?

Source: Source: Pixabay

There are many instances of successful merges between faith-based care and health care which reveal a substantial pool of best practices for confronting the challenging work of bridging the gap. The following are some of the challenges in creating faith-health collaborations, and how best to address those challenges.

Definitions and Terminology

One of the major challenges in creating faith-health collaborations involves definitions and terminology. The concepts of communities of spirit and faith-based, as well as whole person and integrative health, are attractivebut these terms need clear definitions. What are the core components of a whole person that need to be addressed if humans are toflourish? Could faith and health care communities establish a simple set of dimensions for what we consider a whole human being? Perhaps clearly agreeing that humans consist of at least mind, body, spirit, and social dimensions is a start. Then we can agree that providing whole-person integrative health care means taking all these dimensions into consideration, regardless of ones professional lens.

Creating a Common Language

Having common language for communication between faith and health communities is also key. Do love and social support intersect and have similar goals? How about convening and community? At a recent workshop that focused on faith-health care, an attendee spoke of the continuous challenge of attending to the intangible (e.g., prayer, belonging, compassion) and of needing to highlight the negative health aspects of activities that can come from both faith and health communities. For example, one speaker pointed out the negative aspects of some religious behaviors, such as judgment, exclusion, theological ideas that demean . . . or frighten people, and the negative aspects of medical treatment behaviors that perpetuate the racial and ethnic disparities in poor outcomes and low-quality care. It is critical for both sides to understand their strengths and weaknesses.

Answering the "Why"

Repeatedly returning to the why of any collaboration is essential. Isnt the answer to that why always to enhance the health, well-being, and humanflourishing of all people? Another workshop attendee commented on the moral incongruity of faith-based health care organizations acting on the impulse to garner resources and market share in communities at the expense of resources for other key determinants of health, such as adequate housing, education, and so forthcontributing to a health care industry that struggles to improve population health. That observation is key to better aligning resources to help population health strategies succeed.

Finding a Common Moral Ground

Do health care and faith-based care have a common moral basis that guides bothfields toward enhancing population health and well-being? Or do they have different goals that conflict and interfere with each other, leaving the person to contend with only the negatives from both faith care and health care? Hospitals may find themselves in competition with faith-run community health centers (e.g., competition for patients who could visit the emergency department or use primary care services). This competition puts the two immediately at odds, rather than fostering collaboration that could be mutually beneficial.

If faith-based health care prevents the need for high-cost medical industry in the same city, will the more powerful health care organizations restrict the growth and delivery of faith-based health care? So often, world-class health care organizations and hospital systems sit right in the middle of settings for some of the worst health disparities in the country. This is a health-faith issue that needs to be more explicitly addressed. Faith-health collaborations should talk about the imperatives of both the faith and health communitiesbe they moral or economicand how those imperatives can be leveraged to work together on a larger scale to ensure universal access to whole-person health and well-being services for all.

As community, government, and business leaders become aware that health and well-being come primarily from factors outside the medical environment, more partnerships between faith-based and health care organizations like those presented at this workshop will hopefully emerge.

Adapted from "Faith-Health Collaboration to Improve Community and Population Health" by Wayne B. Jonas, MD (Samueli Integrative Health Programs) and Rev. Maeba Jonas, MDiv (Johns Hopkins University), published by the National Academy of Medicine on August 12, 2019. You can read the full article here.

Continued here:
Confronting the Faith-Health Care Gap - Psychology Today

FLOWER MOUND, Texas--(BUSINESS WIRE)--Mannatech (NASDAQ: MTEX), the global health the wellness company, announces the following promotions and changes to their organization, effective immediately. Promoting from within our company shows we are an organization that values our employees and supports an environment of growth and opportunity, said Al Bala, CEO & President.

Dr. Steve Nugent promoted to Chief Health and Nutrition Officer.

With Mannatech since February 1999, Dr. Nugent has 40 plus years of experience in the integrative health and nutrition industry. He has tested more than 6,000 dietary supplement products and has formulated more than 160 dietary products in his career. He earned a PhD in Psychology specializing in health and wellness psychology from the University of the Rockies and earned three degrees with a focus in business administration, including a Masters degree from National University. Dr. Nugent has served as President of the International Association of Complementary Medicine and is President Emeritus of the American Naturopathic Medical Association (ANMA) and is currently a professional member of the American College of Nutrition. In this new role, he will contribute more to the areas of product development, technology, marketing, and corporate sales while continuing to lead the Global Scientific Advisory Board.

Landen Fredrick now has Global Marketing added to his responsibilities and his new title is Chief Sales and Marketing Officer.

Landen has played a key role in strategizing and developing sales strategies to contribute to Mannatechs growth and worldwide success. He has worked closely with the GMs to positively grow and develop the global sales strategies with direct involvement with Korea, Greater China, and North America. In addition to his sales role responsibilities for all markets worldwide, he will now oversee the global marketing operations and will work to facilitate greater collaboration and standardization of marketing resources globally. His goal is to enhance Customer and Associate satisfaction through improved sales and marketing synergy and processes. Landen serves as the Chairman of the Board for the M5M Foundation.

Stephanie Lusk is promoted to Vice President, Global Human Resources.

In her recent role as HR Senior Director, Stephanie oversaw Corporates Human Resources, Benefits, Payroll, Recruiting, Employee Engagement, and other HR-related activities. Stephanie collaborates with her team to bring important infrastructure improvements, effectively using online systems to improve efficiencies, and ensuring Mannatech provides competitive benefit packages for employees while reducing costs. For the past two years she has worked diligently with her team and an outside resource to begin a grass-roots effort to significantly impact the employee engagement within headquarters. She will begin incorporating these practices within other global offices. Her expanded role will now oversee Corporate Facilities and her scope broadens to encompass global HR. Her main focus will be to facilitate the implementation of standardized human resource processes globally including areas of recruiting, onboarding, employee engagement, performance reviews, merits/bonus timelines/processes, employee relations reporting, and exit interviews.

Ron Norman now has Supply Chain and Logistics added to his Treasury, Tax, and Business Systems responsibilities and oversight.

Rons background, knowledge, and involvement of Finance and International Operations, will be beneficial in this expanded role of creating net value, continuing to build a competitive infrastructure, leveraging worldwide logistics, synchronizing supply with demand, and measuring performance globally.

Patty Anthe now leads the Customer Service department in addition to her role of managing Events, Incentives, and Recognition. Her new title is Senior Director, Associate Experience.

Anthe has worked diligently over the past several years to elevate the fields experiences at Corporate-sponsored events, incentive trips, and ensuring proper recognition for the accomplishments of our Associates. Her recent involvement and leadership of the Call Center Care Campaign is one of many items she will work towards in creating a synergistic experience for our Associates and Customers.

For more information please visit http://www.Mannatech.com.

About Mannatech

Mannatech, Incorporated is committed to transforming lives through the development of high quality integrated health, weight management, fitness and skin care products distributed through its global network of independent associates and members. The company has been operating for more than 20 years with operations in 26 markets^. For more information, visit Mannatech.com.

^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

The rest is here:
Mannatech Supports a Strong Workforce by Promoting from Within - Business Wire

5 foods that help you lose weight

It's an amazing world today. With increased longevity, there are many centenarians, but have you heard of supercentenarians, or persons over 110 years? Well, hear about them now! What marks them out? No one knew for long, but now scientists from the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan have an inkling.

Scientists used single-cell RNA analysis to figure out that an exclusive kind of immune cells called cytotoxic CD4 T-cells determine the longevity of humans. The research was published in Proceedings of the National Academy of Sciences (PNAS).

You know that supercentenarians are a class apart because they live longer than most people. However, here are some more amazing facts: firstly, they are "rare". So in Japan in 2015, there were more than 61,000 who crossed 100. Yet there were only 146 supercentenarians. Research also shows that those over 110 years are more resistant to illnesses such as infections and cancer as long as they lived. Hence, they might have a particularly strong immune system, which is under study right now.

Hence, scientists explored the circulating immune cells of supercentenarians and then some younger control groups. They picked out 41,208 cells from seven of the species. It worked out to an average of 5,887 per subject and 19,994 cells for controls (which again meant an average of 3,999 per subject) from five persons in the 50 to 80 group.

Scientists discovered that while the number of B-cells seemed to be lower among supercentenarians, the number of T-cells seemed to be the same, and in fact one subset of T-cells was actually more among supercentenarians. Hence, the supercentenarians seemed to show a larger number of cytotoxic cells that could decimate other cells. Sometimes, they amounted to 80 percent of all T-cells, vis--vis just 10 or 20 percent among controls.

According to Kosuke Hashimoto of IMS, the first author of the paper, "We were especially interested in studying this group of people, because we consider them to be a good model of healthy aging, and this is important in societies like Japan where aging is proceeding rapidly."

IMS Deputy Director Piero Carninci, one of the leaders of the groups, says, "This research shows how single-cell transcription analysis can help us to understand how individuals are more or less susceptible to diseases. CD4-positive cells generally work by generating cytokines, while CD8-positive cells are cytotoxic, and it may be that the combination of these two features allows these individuals to be especially healthy.

"We believe that this type of cells, which are relatively uncommon in most individuals, even young, are useful for fighting against established tumours, and could be important for immunosurveillance. This is exciting as it has given us new insights into how people who live very long lives are able to protect themselves from conditions such as infections and cancer."

See the original post here:
If you are a 110-year-old supercentenarian, thank your cytotoxic T-cells, shows study - International Business Times, Singapore Edition

After weeks of Republican complaints that the Democrats impeachment inquiry relied on secondhand information, the centerpiece of this weeks public hearings is testimony from a man with a direct line to President Donald Trump.

The political peril for Trump, who was dealt a series of setbacks last week, will be heightened as the House investigation accelerates with three days of public hearings starting tomorrow.

No witness is more central than Gordon Sondland, the U.S. ambassador to the European Union, a Trump donor and a confederate with Rudy Giuliani in back-channel diplomatic efforts for the president in Ukraine.

Sondland, scheduled to testify Wednesday, has already amended his previous closed-door testimony once because of discrepancies with other witnesses. And now there will be new questions for him to answer about Trumps pressure on the government in Kyiv to launch a probe entangling former Vice President Joe Biden and other political foes of the president.

David Holmes, a member of the embassy staff in Kyiv, came forward last week to tell impeachment investigators that following a phone conversation between Sondland and Trump, the EU envoy told him the president didnt give a s about Ukraine and that the president only cares about the big stuff that benefits him like the Biden investigation that Giuliani, Trumps personal lawyer, was promoting.

Testimony from Tuesday through Thursday will come from a disparate cast of witnesses, some of whom could prove pivotal to the impeachment inquiry, including officials from the State Department, the White House national security teams, and Vice President Mike Pences office. Read more from Ryan Teague Beckwith and Billy House.

Former Adviser SaysAid Was Tied to Probe: A former top White House adviser told House impeachment investigators Ukrainians were advised Sept. 1 that U.S. military aid was being withheld until their president announced an investigation of a company that had hired Bidens son, Hunter. Tim Morrison, a former senior director of European and Russian affairs at the National Security Council, said Sondland told him how he had informed a high-ranking Ukrainian official that release of $400 million in aid was being linked to the investigations, according to a transcript of his closed-door testimony released Saturday.

The House committee also released testimony from Jennifer Williams, an aide to Vice President Mike Pence, who said she found some of the discussion on the July 25 call between the two leaders to be unusual and inappropriate. Read more from Billy House.

Funding Deadline: Lawmakers are facing a deadline of Thursday to pass legislation to continue funding the government, before they depart for a recess through the week of Thanksgiving. House and Senate leadership have expressed optimism that both chambers will pass a measure ahead of the deadline, though no continuing resolution has been introduced as of this morning and the House schedule offered few details of the timing of a vote.

I hope we pass the CR, House Majority Leader Steny Hoyer (D-Md.) said on the floor Friday. I hope its as clean as it can be. The measure will contain some usual anomalies, noncontroversial changes in funding levels or legislative language, Hoyer said.

FDA Pick to Face Questions on Frankenfish, Stem Cells, Vaping: Trumps selection to be the next head of the FDA will face a barrage of questions this week about his views on vaping, oversight of stem-cell therapies and even Frankenfish. Stephen Hahn, chief medical executive of the prestigious MD Anderson Cancer Center at the University of Texas in Houston, will go before the Senate Health, Education, Labor and Pensions Committee Wednesday for his first public hearing since being nominated to become commissioner of the Food and Drug Administration. Alex Ruoff details what to expect.

Risch Warns Erdogan of Sanctions: Senate Foreign Relations Chairman Jim Risch (R-Idaho) warned that if Turkish President Recep Tayyip Erdogan persists in the deployment of a Russian air defense system, he will move ahead with a sanctions bill. It is his choice, and he knows the consequences, Risch said in a statement on Friday evening. Just a day earlier, Risch had said that the Senate should hold off on sanctions over Turkeys invasion of Syria if Erdogan agreed to give up the S-400 anti-aircraft missile system. Read more from John Harney.

Anti-Robocall Agreement Reached: House and Senate negotiators on Friday reached an agreement on bipartisan legislation to combat illegal robocalls, and anticipate a vote on the measure this year. The House and Senate passed separate legislation earlier this year with broad bipartisan support, and staff has been working since August to reach an agreement on provisions from the two anti-robocall bills. Read more from Rebecca Kern.

Democrats Subpoena EPA Over Formaldehyde Analysis: Rep. Eddie Bernice Johnson (D-Texas), chairwoman of the House Science, Space, and Technology Committee, sent two subpoenas to the EPA Friday over the agencys alleged refusal to provide answers about removing formaldehyde from its review program outlook. Johnson said in an accompanying letter to EPA Administrator Andrew Wheeler that the committee had suffered through eight months of delayed and insufficient responses. The subpoenas were sent to Wheeler and David Dunlap, deputy assistant administrator for the agencys Office of Research and Development. Read more from Stephen Lee.

Democrats Use Super-PACs to Combat Trump: Wealthy Democratic donors are pouring money into outside groups as part of their effort to defeat Trump in 2020, avoiding contributions to a party apparatus that lost in 2016 and to leading candidates who dont want their help. Outside groups aligned with Democrats have pledged to spend more than $300 million attacking Trump, far more than the $67 million raised by the Democratic National Committee. With little primary opposition, Trump and the Republican Party are already in general election mode, free to spend millions in states hell need to win a second term. The Democratic groups are being fueled by seven-figure checks necessary to advertise in battleground states, blunting Trumps big campaign cash advantage. Read more from Bill Allison.

Buttigieg Wants Public College Free for Some: Pete Buttigieg called for spending $120 billion on the Pell Grant program and making public colleges tuition-free for students eligible for those federal grants as part of his proposal released Monday to improve college affordability. Unlike some of his primary opponents, Buttigieg isnt calling for public colleges to be tuition-free for all students, or for total student-debt cancellation. Hes said families that make over a certain income threshold should pay at least some of the cost of their kids higher education. The plan released Monday focuses on helping lower- and middle-income families. Read more from Tyler Pager.

Louisiana Governors Re-election May Offer Lessons for 2020: John Bel Edwards proved its possible to buck Trumps popularity, winning a second term to remain the only Democratic governor in the Deep South. His victory will give political strategists important insights on what it takes to motivate turnout going into 2020, said University of Pennsylvania political science professor Daniel J. Hopkins. Voters may feel more empowered to back a moderate Democrat, said Hopkins, who explores the nationalization of state politics in his book, The Increasingly United States.

In Louisiana, Trump headlined three rallies to try to drive turnout for Republican Eddie Rispone. Edwards, meanwhile, ran on a record of demonstrated independence from his national party. Read more from Jennifer Kay.

North Carolina Lawmakers Back New Congressional Map: North Carolina lawmakers have approved new congressional boundaries to be used in the 2020 elections. The 13 current U.S. House district lines were redrawn after a state court decided Oct. 28 that the map in place since 2016 couldnt be used, pending further review. The North Carolina Superior Court for Wake County had found that plaintiffs were likely to prevail in a lawsuit claiming the boundaries were illegally drawn to maximize Republican advantage. Read more from Andrew M. Ballard.

Barr Blasts Democrats: Attorney General William Barr fired a broadside against critics of Trump and congressional Democrats in particular while defending the presidents actions. In a fiery speech before the conservative Federalist Society on Friday, Barr said Trumps opponents are using every tool they can to intentionally sabotage his administration. Immediately after President Trump won election, opponents inaugurated what they called the Resistance, Barr said. They essentially see themselves as engaged in a war, to cripple by any means necessary, a duly elected government. Read more from Chris Strohm.

Trump, Kim at Odds Ahead of Deadline: The bonhomie between Trump and North Korean leader Kim Jong Un is nearing a key deadline showing new signs of strain. Trump urged Kim over the weekend to act quickly to get a nuclear deal done, suggesting the two leaders could meet again soon. His comments came hours after North Korea ruled out nuclear talks without a policy change by the U.S. and reported on a military drill observed by Kim himself.

Veteran North Korea nuclear adviser Kim Kye Gwan told Trump that Pyongyang will no longer give him things to boast about, the states official KCNA news agency today quoted him as saying. He added North Korea is no longer interested in talks that the U.S. uses to buy time. Read more from Glen Carey and Jihye Lee.

Lawmaker Speaks Out Against U.S. Defense-Cost Hike: Rep. Grace Meng (D-N.Y.) said Trump is destabilizing the U.S.s relationship with South Korea by demanding the Asian nation pay about $5 billion, or five times the amount of its current one-year deal, to host U.S. troops, Jihye Lee reports. Meng tweeted a letter Friday asking Defense Secretary Mark Esper and Secretary of State Michael Pompeo to devise a better strategy that values the alliance, adding that such a hike would be extorting South Korea. Meng said such a request also puts U.S. national security and economic interests in jeopardy. She asked the U.S. officials to reconsider and engage in good faith negotiations.

Esper Has Great Faith in U.S. Military Justice System: Secretary Esper expressed his faith in the countrys military justice system, after Trump last week pardoned two soldiers convicted in Afghanistan killings, Glen Carey reports. Id say first of all that we have a very effective military justice system, Esper said during a press conference at the Asean Defense Ministers Meeting-Plus in the Thai capital of Bangkok yesterday. U.S. military personnel are trained from day one about the laws of armed conflict and how to conduct themselves during wartime, he said.

China, U.S. Trade Talks Continue: Top negotiators from China and the U.S. talked again this weekend, after signs of concessions from both sides on some of the outstanding issues. Chinas Vice Premier Liu He, the countrys key negotiator in the trade talks with the U.S., spoke with Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer by phone on Saturday morning Beijing time, according to the Chinese Commerce Ministry. They had constructive discussions about each sides core concerns in the phase-one deal, and agreed to stay in close communication, the statement said. The USTR confirmed the call took place. Read more.

Trump to Tour Apples Austin Plant: President Donald Trump is scheduled to tour an Apple manufacturing plant in Austin, Texas, on Wednesday, the White House said yesterday. The president plans to visit the plant along with Apple CEO Tim Cook, according to a tweet by spokesman Judd Deere. The Austin American-Statesman newspaper reported that Trump will travel with Treasury Secretary Steven Mnuchin and other administration officials.

The company announced in September that its new Mac Pro computer will be assembled in Texas after it received exclusions from the Trump administration from tariffs on certain parts imported from China. The visit also comes at a time the U.S. and China are close to finalizing the first phase of a highly-anticipated trade deal. Read more from Hailey Waller.

Facebook, Google Donate Heavily to Privacy Advocacy Groups: Few companies have more riding on proposed privacy legislation than Google and Facebook. To try to steer the bill their way, the giant advertising technology companies spend millions of dollars to lobby each year, a fact confirmed by government filings. Not so well-documented is spending to support highly influential think tanks and public interest groups that are helping shape the privacy debate, ostensibly as independent observers.

Bloomberg Law examined seven prominent nonprofit think tanks that work on privacy issues that received a total of $1.5 million over an 18-month period ending Dec. 31, 2018. The groups included such organizations as the Center for Democracy and Technology, the Future of Privacy Forum and the Brookings Institution. The actual total is undoubtedly much higherexact totals for contributions were difficult to pin down. Read more from Daniel R. Stoller.

Scalia Says Big Law is Unwilling to Defend Conservative Views: Major law firms are shying away from defending conservative viewpoints in court, a trend that should trouble the legal profession, Labor Secretary Eugene Scalia told a group of right-leaning lawyers at a Federalist Society event on Friday. It is appropriate, admirable, and necessary for lawyers to take on clients and advance positions that may offend some observers, Scalia said. But some of the countrys biggest law firms appear to be disinclined to protect free speech and free trade in ideas, he argued, calling that evidence of a broad trend of conservative political views being under attack. Read more from Jaclyn Diaz.

To contact the reporters on this story: Zachary Sherwood in Washington at zsherwood@bgov.com; Brandon Lee in Washington at blee@bgov.com

To contact the editors responsible for this story: Giuseppe Macri at gmacri@bgov.com; Loren Duggan at lduggan@bgov.com

Read this article:
What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government

Conference Call and Webcast Today at 8:00 a.m. Eastern Time

Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue, Appointment of CFO, Phase 2 in Progressive MS Continues to Enroll Patients

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September 30, 2019 and recent corporate updates.

On October 11, 2019 we reached a major corporate milestone by fully enrolling 200 patients in the Phase 3 clinical trial of NurOwn in ALS (Amyotrophic Lateral Sclerosis). Additionally, on October 28, we announced that we received notification from the NurOwn Data Safety Monitoring Board (DSMB) that after reviewing all of the safety data as of September 30, the study should continue without any changes in the protocol. The DSMB indicated they did not identify any significant safety concerns, stated Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics. He added, Our Phase 2 trial of NurOwn in Progressive MS (Multiple Sclerosis) continues to enroll patients in several of the leading U.S. medical centers and we anticipate announcing additional investigational centers of excellence in the near future. The first eight (8) participants have been enrolled in the study.

Third Quarter 2019 and Recent Corporate Highlights:

Financial Results for the Three Months Ended September 30, 2019

For further details on BrainStorms financials, including financial results for the three months ended September 30, 2019, refer to Form 10-Q filed with the SEC on November 14th, 2019.

Conference Call and Webcast: Thursday, November 14, 2019 @ 8:00 a.m. Eastern Time

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe-Harbor StatementStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)U.S. dollars in thousands(Except share data)

View post:
BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire

Having great eyesight is something most people take for granted. Rather than failing to take care of your eyesight, you need to work hard to have this vital part of your body inspected on a regular basis. Nearly 25 million Americans are affected by serious eye problems like cataracts. Early detection is a key component of successfully treating eye conditions.

Most people fail to realize that most major health insurance plans dont have vision coverage. Instead of paying out of pocket for things like glasses or eye exams, work on getting a supplemental vision insurance policy. With all of the different supplemental vision insurance plans on the market, finding the right one will be hard work. Rushing through this important decision is a recipe for disaster, which is why weighing all of your options is crucial.

Read below for a list of considerations that need to be made before choosing a supplemental vision insurance plan.

The biggest misconception most Medicare recipients have is that vision coverage comes with each plan. In reality, Parts A and B do not allow recipients to get coverage for routine vision care. The best way to ensure this does not become a financial burden is by seeking out a Medicare Advantage plan. There are a variety of Advantage plans that feature vision coverage.

Ideally, you want to choose an Advantage plan that covers both preventative care and treatment for serious eye-related problems like retinal detachment and macular degeneration. The more you know about the various Medicare Advantage plans at your disposal, the easier it will be to be the right one selected.

Checking on the HealthMarkets website is a great way to get the best vision insurance for an affordable price. This website provides information about a host of Medicare Advantage plans, which means narrowing down your policy options will be a breeze.

Having 20/20 vision is something most people take for granted. Unfortunately, as a person ages, their vision will begin to get worse. Instead of thinking you can get by without vision coverage because your eyes are currently in good shape is a horrible mistake. This error can lead to you paying for serious eye care procedures out of pocket. While this may not sound like a big deal, it can actually put you in a financial bind.

Instead of waiting until you are saddled with a large bill for eye surgery, you need to seek out comprehensive coverage. Allowing an insurance agent to weigh in on this important decision is vital. With their guidance, you should have no problem getting the best vision insurance policy to fit your needs.

Being a parent is one of the most important jobs you will take on in this lifetime. Keeping your child happy and healthy should be one of the biggest concerns you have. Making sure your little one can get routine eye exams and glasses when needed is crucial. The best way to avoid problems with providing this care to your child is by finding the right vision insurance policy.

In order for a child to qualify for a joint policy with their parent, they will need to be under the age of 18. Before choosing a particular eye insurance policy, consider how much preventative care it approves. Ideally, you want to choose a policy that allows you and your child to get yearly eye exams free of charge.

While a great supplemental vision insurance policy will cover the majority of the care you receive, there may be some out of pocket costs. Finding out what these costs will be before choosing a particular policy is important. Ignoring the need for this information may lead to you being overwhelmed with the cost later on.

Some people make the mistake of looking at a few supplement eye insurance policies and making a decision out of desperation. Doing this may lead to the wrong policy being chosen, which is why you need to weigh every option before signing off on a supplement insurance policy.

Excerpt from:
Trying to Get the Right Supplemental Vision Insurance Plan? Consider These Helpful Tips! | PVP - PVP Live

A health worker conducts a cataract screening in Sierra Leone. Photo by: Mustafa ztrk / IHH Humanitarian Relief Foundation/ CC BY-NC-ND

Imagine being unable to see when a 20-minute operation could restore your sight, or unable to work or succeed in school because you need a pair of glasses. It may seem unthinkable. Yet this is the realityfor hundreds of millions of people suffering from poor vision in countries with insufficient health care resources. And as the worlds population grows and ages, global blindness and visual impairment are expected to tripleover the next three decades. A crisis is on the horizon that, if left unaddressed, could lead blindnessto increaseto 115 million people globally, with another 588 million suffering from moderate or severe vision impairment.

These are alarming statistics. But the good news is that 75% of all blindness and visual impairment is treatable or preventable. If we are to avoid a looming crisis, we must be strategic in how we target and scale up our efforts and we must start now. Heres how.

First, we must upskill local eye health teams to provide consistent care for their communities over the long term. We know that it is not enough to drop in health services to rural and resource-poor communities. As heads of the worlds four leading not-for-profit eye health organizations, our teams have more than 240 years of combined experience in 55 countries, including in Asia and sub-Saharan Africa.

Those areas are home to the vast majority of visually impaired people and, not coincidentally, are where health systems are in crisis due to a lack of medical professionals, including eye health workers. Meeting demand means providing quality training not just for surgeons, but also nurses, social workers, and support staff who can help to share the work of patient care.

Second, it will be essential to utilize innovative teaching tools and technology to take programs to scale and further our reach. The number of people in need of eye care worldwide is outpacing the number of trained ophthalmologists. Remotely connecting eye health professionals with experts across the world is one way to turn the tide.

Likewise, using tools such as artificial intelligence and telemedicine to more efficiently screen and diagnose common conditions will become the way of the future. Doing so will ensure communities without access to eye care can undergo routine checkups at local clinics, only receiving referrals to larger, and often distant, health centers when necessary, reducing the burden on doctors and patients alike.

Finally, we must join forces. Now is the time to act by collaborating to create sustainable eye health resources. We have already seen examples of whats possible when like-minded organizations join forces to amplify their impact. For example, Vision 2020 a global project of the World Health Organizationand the International Agency for the Prevention of Blindnessto decrease avoidable blindness, ending next year has reduced blindness down to 36 million people in the world at a time when the number of blind people had been projected to double.

Together with global partners, our four organizations have played a leading role in reducingthe number of people at risk of trachoma the leading cause of infectious blindness around the world by an astounding 91% since 2002.

WHO recently published its first-ever World Report on Vision, which reinforces the urgency of the crisis. The report says there are 2.2 billion people in the world with impaired vision and, for at least 1 billion of them, it could have been prevented or treated. We hope the report helps galvanize and support governments, particularly in low- and middle-income countries, to strengthen their eye care systems and deliver on the commitments made by governmentsduring the U.N. General Assembly in September to address eye health needs as part of universal health coverage.

Get development's most important headlines in your inbox every day.

Thanks for subscribing!

When people cannot see, it can be much harder for them to actively participate in their local economies and social engagements, such as finding and keeping a job, attending family celebrations, or even running errands and completing chores. Blindness can result in social isolation and a higher risk of death related to depression and falls.

Blindness and visual impairment can trap families in a cycle of poverty. On the flip side, we know that every $1 invested in eye health in developing countries resultsin $4 in economic gain. Consider that the most prevalent causes of avoidable blindness and visual impairment are cataractsand refractive errors, such as nearsightedness, farsightedness, and astigmatism. These common conditions can be easily corrected, delivering benefits far beyond restoring sight.

A World Bankreport declared routine cataract surgery one of the most cost-effective public health interventions, while a recent studyamong tea pickers in India showed that simply providing a pair of glasses led to marked improvements in productivity and earnings, with results even higher among workers over the age of 50.

Poor vision is also a gender equity issue. Currently, 55%of the worlds blind or visually impaired people are women and girls. Efforts to ensure access to eye care will particularly benefit them, and if we address this issue, they will be better able to contribute to community life and seek education and employment.

Our vision is clear: With these approaches, we can fight this crisis and improve the future of people and communities around the world. Many problems facing humanity appear intractable, but this is one problem we know how to resolve.

Devex, with financial support from our partner Essilor, is exploring challenges, solutions, and innovations in eye care and vision. Visit the Focus on: Visionpage for more.

Go here to see the original:
Opinion: A vision crisis is looming unless we act now - Devex

(PRESS RELEASE) BRIDGEWATER, NJ Bausch + Lomb, a leading global eye health company, in collaboration with TerraCycle, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste, announces the donation of custom training modules to the Guide Dog Foundation, a national not-for-profit that trains guide dogs for people who are blind or visually impaired. The training modules, including benches, tables, waste stations and an agility ramp, were made from used contact lens materials collected through the Bausch + Lomb ONE by ONE Recycling Program, the first and only contact lens recycling program of its kind in the United States, along with other recycled material.

The training modules will be presented to the Guide Dog Foundation at its headquarters in Smithtown, N.Y., and will be utilized in the training of guide dogs for individuals who are blind or visually impaired as well as helping to further enhance the campus for those who visit.

The ONE by ONE Recycling program and our collaboration with TerraCycle is representative of our companys long-standing commitment to sustainability. With this donation, were taking this program one step further, bringing new life to these materials by supporting the work of the Guide Dog Foundation, an organization that provides sight through the magnificent work of guide dogs for people who are blind or visually impaired, said John Ferris, general manager, U.S. Vision Care, Bausch + Lomb.

We are grateful for the efforts of Bausch + Lomb and TerraCycle in reducing the environmental waste of contact lenses while also making this critical donation to help improve the lives of those who are blind or visually impaired, said John Miller, CEO, Guide Dog Foundation. These training modules will be a wonderful addition to our training facility where our instructors train guide dogs the significant skills and tasks they need to increase the independence and mobility for people living with these conditions.

Since its inception in Nov. 2016, the ONE by ONE Recycling program has collected nearly 16 million used contact lenses, blister packs and top foils, which equates to more than 95,000 pounds of waste, making a significant impact on reducing the waste associated with contact lens use, especially daily disposable lenses. The donation to the Guide Dog Foundation is in recognition of this milestone and in commemoration of America Recycles Day (Friday, Nov. 15, 2019), the programs third anniversary.

We are delighted to celebrate America Recycles Day and the third anniversary of the Bausch + Lomb ONE by ONE Recycling program through the donation of these materials to the Guide Dog Foundation, said Tom Szaky, founder and CEO, TerraCycle. Before the ONE by ONE Recycling program, contact lenses were one of the forgotten waste streams that were often overlooked due to their size. In the three years since the implementation of the program, weve seen positive momentum from contact lens wearers who continue to use this program. Together we are helping to preserve our environment and transitioning these materials back into the world in a positive way its a win-win for all.

The ONE by ONE Recycling program encourages contact lens wearers to bring their used contact lenses and packaging to any one of the more than 4,200 participating eye care professionals offices to recycle them in custom recycling bins provided by Bausch + Lomb. Once the recycling bins are full, the optometry practice mails the materials to TerraCycle using a free shipping label from http://www.bauschrecycles.com. The materials are then received by TerraCycle, where the metal layers of the blister packs are recycled separately, while the contact lenses and plastic blister pack components are melted into plastic. These materials can then be remolded into new recycled products, such as the training modules donated to the Guide Dog Foundation.

In addition to the training module donation made to the Guide Dog Foundation, the ONE by ONE Recycling Program donates $10 to Optometry Giving Sight, the only global fundraising initiative that specifically targets the prevention of blindness and impaired vision by providing eye exams and glasses to those in need, for every 10 pounds of contact lens waste collected from participating ONE by ONE recycling centers.

The donation to the Guide Dog Foundation was funded through the Bausch Foundation (www.bauschfoundation.org), which was established in 2017 to improve the lives of patients globally by providing access to safe, effective medicines and by financially supporting health care education and causes around the world.

For more information on the Bausch + Lomb ONE by ONE Recycling program, visit http://www.bauschrecycles.com

The rest is here:
American Diabetes Association and VSP Vision Care Collaborate to Save Sight for People with Diabetes - InvisionMag

First-of-its-kind(1)contact lens delivers superior visual performance(2)with seamless adaptation to light day and night(3)

The UK is the first market in EMEA to make the contact lens widely available amidst findings that 70% of Britons' eyes are bothered by light(4)

LONDON, Nov. 19, 2019 /PRNewswire/ --Johnson & Johnson Vision* today announced the national availability of ACUVUE OASYS with Transitions Light Intelligent Technology in the UK. The first-of-its-kind1photochromic contact lens offers superior visual performance indoor and outdoor, day and night.

Named one of TIME magazine's best inventions, ACUVUE OASYS with Transitions combines the proven comfort and vision performance of ACUVUE OASYS5, with the ability to reduce the stressful impact that light can have on your eyes++3. The lens also reduces halos and starbursts around bright lights at night, delivering more effortless sight with less squinting.6++

A recent survey commissioned by Johnson & Johnson Vision found 70% of Britons' eyes are bothered by light, which can result in feelings of eye tiredness, distraction and discomfort. The survey revealed driving is the most common situation causing Brits to be bothered by light (56%), followed by the change of moving from dark to light environments, such as leaving a cinema or shopping centre (51%).

The awareness of the impact of light on eye health is also growing, with half of UK respondents (52%) indicating they are concerned about the impact of light on their eyes.

In response, 94% of UK adults who are bothered by light are turning to solutions to cope and protect their eyes, by shading their eyes (74%), squinting (71%) and turning down screen brightness (47%).

Speaking about the new product, Jakob Sveen, Director Northern European Cluster and General Manager UK & Ireland, Johnson & Johnson Vision said: "We are excited to bring ACUVUE OASYS with Transitions Light Intelligent Technology to the UK. In Europe, 64% of those who stop wearing reusable contact lenses do so because of performance and comfort issues7. Consumers are demanding more from their contact lenses beyond improved sight alone which is what makes this contact lens so great. We believe this technology will be a game changer for the health and eye care industries, giving contact lens wearers superior visual performance over any other contact lens on the market."

The creation of the ground-breaking lens follows more than a decade of work by Johnson & Johnson Vision in partnership with Transitions Optical Limited, the leading provider of photochromic (smart adaptive) eyeglass lenses worldwide. The two organisations are working together to research and deliver best-in-class vision care innovations.

Johnson & Johnson Vision is collaborating with UK influencers and athletes, such as marathon runner Matt Rees, to share how light affects their eyes and visual performance every day, and the benefits that ACUVUE OASYS with Transitions can bring to a range of situations, whether it is commuting in and out of the office, attending an event, playing sports or driving at night.

ACUVUEOASYS with Transitions is a two-week reusable contact lens. It is now commercially available at select retailers in the UK and is being rolled-out to other markets in EMEA. Anyone interested in the lens should speak with an eye care practitioner for a prescription. For more information or to find an eye care professional near you, visit https://www.acuvue.co.uk. Follow the conversation on Instagram and Facebook.

Survey Methodology Johnson & Johnson Vision Care Inc. and TRUE Global Intelligence, the in-house research practice of FleishmanHillard, conducted a 10-minute online survey among a nationally representative sample of 1,047 UK adults, 18 years of age and older, from 19 February through 13 March, to explore the prevalence of light sensitivity among consumers. The margin of error is +/-3 percent at a 95% confidence level.

About Johnson & Johnson VisionAt Johnson & Johnson Vision,part ofJohnson & JohnsonMedical Devices Companies**,we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better and live better. Visit us atwww.jnjvisioncare.co.uk/. Follow@JNJVisionon Twitter andJohnson & Johnson Visionon LinkedIn.

About Johnson & Johnson Medical Devices Companies As the world's most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we're working to profoundly change the way care is delivered. We are in this for life.

**Comprising the surgery, orthopaedics, vision and interventional businesses within the Johnson & Johnson's Medical Devices segment

ImportantInformationfor Contact Lens Wearers:ACUVUE Brand Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and lens care instructions provided by your optician. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your optician immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call 0800 022 4222 or visit http://www.acuvue.co.uk

All ACUVUE Brand Contact Lenses have Class 1 or Class 2 UV Blocking to help provide protection against transmission of harmful UV radiation to the cornea and into the eye. UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area.

The third-party trademarks used herein are trademarks of their respective owners.

ACUVUE and ACUVUE OASYS are registered trademarks of Johnson & Johnson Medical Ltd 2019. Transitions is a registered trademark, the Transitions logo, Transitions Light Intelligent Technology and Transitions Light Intelligent Lenses are trademarks of Transitions Optical, Inc. used under license by Transitions Optical Limited. 16OctUK3734

Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC

* Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC JJV Data on File 2018: Definition of ACUVUE OASYS with Transitions Light Intelligent TechnologyTIME recognized ACUVUE OASYS with Transitions as one of their Best Inventions of 2018.++Compared to ACUVUE OASYS with HYDRACLEAR PLUS

1FDA Press Release: FDA clears first contact lens with light-adaptive technology https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604263.htm April 10, 2018.2 JJV Data on File 2018. ACUVUE OASYS with TransitionsTM Light Intelligent TechnologyTM Objective and Subjective Clinical.3 JJV Data on File 2018. Definition of ACUVUE OASYS with Transitions Light Intelligent Technology.4JJV and FH TRUE Global Intelligence 2019 UK Survey5 ACUVUEOASYS has never been beaten in comfort.www.clinicaltrials.govis a website maintained by the NIH. The 23 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUEOASYS Brand with HYDRACLEARPlus or ACUVUE OASYS 1-Day with HydraLuxe Technology. Review conducted as of August, 2018.6AAO Academy 2018 Presentation: The Impact of Photochromic Contact Lenses on Daytime and Nighttime Driving Performance, John Buch, OD, FAAO. Available at: https://www.jnjvisionpro.com/sites/us/files/public/Grants/Academy/jjv_academy2018_clinicalresearchinnovations_final.pdf (page 13). November 7, 2018.7JJV Data on file 2019: Data substantiation for P2P Poland, Italy, Germany, France, UK and Denmark.

Logo - https://mma.prnewswire.com/media/600714/Johnson_and_Johnson_Vision_Logo.jpg

http://www.its.jnj.com

SOURCE Johnson & Johnson Vision

View post:
Johnson & Johnson Vision Announces National Availability of ACUVUE OASYS with Transitions Light Intelligent Technology in the - PR Newswire UK

After a brief spell of breathable air, the air quality index has dipped yet again and the hazardous pollution levels are making it difficult to breathe well.We all know that air pollution carries along with serious health implications and leads to a host of issues. Difficulty breathing, congestion, compromised immunity, allergies, headaches are impacting everybody. Apart from this, pollution can also affect you in sneaky little ways, even potentially troubling your eyesight!Bad air quality has to lead to people complaining of eye problems and allergies, which need to be attended at once. Since you are constantly being exposed to smog, the pollutants find an easy way to settle in-between eye cavities and harm your vision. Some of the most visible symptoms of pollution include the following:-Water eyes-Sore eyes-Redness, swelling, itching sensation-Experiencing discomfort or a burning sensation.-Dry eyes and allergy.-Blurring and hazy vision.

If you experience any of these symptoms, practice care and avoid further exposure. The last thing you want is for the pollutants to impact your vision. There are also some ways you can protect your eyes from the nasty air pollution.

Stay hydratedIt is very important to not miss out on the water intake. Make sure to drink lots of water. It washes away the toxins as well as helps support tear formation in the eyes, which is an important function that protects against dry eyes syndrome and gets rid of irritants that may lurk beneath your eyelids.

Blink your eyes more oftenOne of the simplest ways you can undo the damage done by pollution is by blinking your eyes properly. When you blink, a special protective tear film is produced which protects your eyes, provides moisture and does not let the pollutants settle in.

Pay attention to your dietJust like the foods, you eat can clear out nasal passageways and strengthen your immunity, the same applies to your eyesight. Your daily food intake should include ample Vitamin A, Omega-3 fatty acid content, apart from green leafy vegetables and fruits. All of these food groups are good for your eyes.

Continued here:
Burning, itchy eyes during pollution? Here's what to do - Times of India